PHARMACOLOGIC EVALUATION OF 3 DOSES OF TESTOSTERONE IN MEN WITH HYPOGONADISM

本研究是一项单中心、开放标签研究，旨在评价 含有睾酮的凝胶的作用和药代动力学， 渗透促进剂，SEPA（MC-T凝胶），当剂量增加时 （0.25克至1.0克）的男性性腺功能减退症。目标是确定 这种新的睾酮抑制剂对循环睾酮的影响 程度.此外，血清睾酮水平将与那些 在对Androderm（Smith-Kline Beecham）的反应中观察到， 睾丸激素制剂，可通过药物获得。患者 Androderm的接受度并不高，因为它的表面积很大 和严重的皮肤刺激。希望MC-T 凝胶将成为一种新的，更灵活的治疗方法， 性腺功能减退的男人

This study is a single-center, open labeled study to evaluate the effects and pharmacokinetics of a gel containing testosterone and the penetration enhancer, SEPA (MC-T Gel), when adminsitered in rising doses (0.25gm to 1.0gm) to men with hypogonadism. The goal is to identify the effects of this new testosterone prepartion on circulating testosterone levels. In addition, serum testerone levels will be comared to those seen in response to Androderm (Smith-Kline Beecham), a transdermal testosterone preparation that is commerically available. Patient acceptance of Androderm has not been high, due to the large surface area of the patches and significant skin irritation. It is hoped that MC-T gel will turn out to be new, more flexible treatment, option for hypogonadal men.